Literature DB >> 23117943

Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Amanda C Peltier1, Peter D Donofrio.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy. Multiple diagnostic criteria have been established, with the primary goal of identifying neurophysiologic hallmarks of acquired demyelination. Treatment modalities have expanded to include numerous immunomodulatory therapies, although the best evidence continues to be for corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg). This review describes the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117943      PMCID: PMC4845954          DOI: 10.1055/s-0032-1329194

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  119 in total

1.  Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population.

Authors:  M Iijima; H Koike; N Hattori; A Tamakoshi; M Katsuno; F Tanaka; M Yamamoto; K Arimura; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-01-25       Impact factor: 10.154

2.  Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.

Authors:  N Mowzoon; A Sussman; W G Bradley
Journal:  J Neurol Sci       Date:  2001-04-01       Impact factor: 3.181

3.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

4.  Interferon beta-1a as an investigational treatment for CIDP.

Authors:  J-M Vallat; A F Hahn; J-M Léger; D P Cros; L Magy; F Tabaraud; P Bouche; P-M Preux
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

5.  [Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels].

Authors:  Akiko Takeuchi; Shinichi Shirai; Kazuhiro Horiuchi; Ikuko Takahashi; Masaaki Matsushima; Makoto Hirotani; Takahiro Kano; Ichiro Yabe; Akihisa Matumoto; Hidenao Sasaki
Journal:  Rinsho Shinkeigaku       Date:  2012

6.  Mycophenolate in treatment-resistant inflammatory neuropathies.

Authors:  T Umapathi; R Hughes
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

7.  Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP.

Authors:  C Sommer; S Koch; M Lammens; A Gabreels-Festen; G Stoll; K V Toyka
Journal:  Neurology       Date:  2005-12-27       Impact factor: 9.910

8.  Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant?

Authors:  Gauthier Remiche; Alain Kentos; Nicolas Mavroudakis
Journal:  Acta Neurol Belg       Date:  2010-03       Impact factor: 2.396

Review 9.  Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.

Authors:  Kenneth C Gorson; Anthony A Amato; Allan H Ropper
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

10.  Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.

Authors: 
Journal:  Lancet Neurol       Date:  2009-01-10       Impact factor: 44.182

View more
  15 in total

Review 1.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

2.  Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.

Authors:  Laura Fionda; Antonella Di Pasquale; Stefania Morino; Luca Leonardi; Fiammetta Vanoli; Simona Loreti; Matteo Garibaldi; Antonio Lauletta; Girolamo Alfieri; Elisabetta Bucci; Marco Salvetti; Giovanni Antonini
Journal:  J Neurol       Date:  2021-02-27       Impact factor: 4.849

3.  A Rare Case of COVID-19-Induced Chronic Demyelinating Polyneuropathy.

Authors:  Dhaval Patel; Gaurav Mandal; Lawrence Chukwueke; Kenneth Woods
Journal:  Cureus       Date:  2022-05-20

Review 4.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

5.  Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Fwad Nicknafs; Naghme Nazer; Arezou Sayad; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 6.  Intravenous immunoglobulin therapy: a snapshot for the internist.

Authors:  Gianfranco Vitiello; Giacomo Emmi; Elena Silvestri; Gerardo Di Scala; Boaz Palterer; Paola Parronchi
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 5.472

Review 7.  Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Authors:  Melvin Berger; Jeffrey A Allen
Journal:  Muscle Nerve       Date:  2015-01-29       Impact factor: 3.217

Review 8.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

9.  Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report.

Authors:  Lesia Rozłucka; Elżbieta Semik-Grabarczyk; Marta Pietrukaniec; Agnieszka Żak-Gołąb; Małgorzata Grabarczyk; Sebastian Grosicki; Michał Holecki
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

10.  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE).

Authors:  Hrudya Abraham; Jose Kuzhively; Syed W Rizvi
Journal:  Am J Case Rep       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.